Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
OVERLAP
8%
OVERLAP
BY WEIGHT
BY WEIGHT
4
# OF OVERLAPPING HOLDINGS
PBE
28
HOLDINGS
14%
ALSO IN CANC
CANC
48
HOLDINGS
8%
ALSO IN PBE
SECTOR DRIFT (PBE minus CANC)
OVERLAPPING HOLDINGS
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in PBE |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
AMGEN INC | 4.8% | 3.3% | 3.3% |
|
EXELIXIS INC | 2.7% | 4.1% | 2.7% |
|
GILEAD SCIENCES INC | 4.9% | 1.4% | 1.4% |
|
ILLUMINA INC | 5.6% | 0.6% | 0.6% |
PBE Overweight Relative to CANC
|
ALNYLAM PHARMACEUTICALS INC | 5.4% |
|
ROYALTY PHARMA PLC CLASS A | 5.3% |
|
ILLUMINA INC | 4.9% |
|
VERTEX PHARMACEUTICALS INC | 4.8% |
|
BIOMARIN PHARMACEUTICAL INC | 4.6% |
|
UNITED THERAPEUTICS CORP | 4.4% |
|
GILEAD SCIENCES INC | 3.5% |
|
ANAVEX LIFE SCIENCES CORP. | 3.4% |
|
BLUEPRINT MEDICINES CORP. | 3.4% |
|
PROTAGONIST THERAPEUTICS, INC. | 3.2% |
PBE Underweight Relative to CANC
 |
ROCHE HOLDINGS LTD-SPONS ADR | -5.3% |
|
ELI LILLY & CO | -5.2% |
|
BRIDGEBIO PHARMA, INC. | -4.9% |
|
REVOLUTION MEDICINES, INC. | -4.9% |
|
NOVARTIS AG | -4.4% |
 |
ASTRAZENECA PLC | -4.1% |
 |
MERUS N.V. | -3.8% |
 |
GENMAB A/S SPONSORED ADR | -3.7% |
|
NUVALENT, INC. CLASS A | -3.5% |
|
BRISTOL-MYERS SQUIBB CO | -3.5% |